Genmab A/S
GMABHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeGenmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. At a $26.93B market cap, Genmab A/S ranks as a large-cap company within healthcare. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Market Cap
$26.93B
Beta
0.65
P/E (TTM)
34.21
P/E (Fwd)
28.90
EPS (TTM)
$1.28
EPS (Fwd)
$1.51
ROE
14.0%
ROA
8.8%
Cash
$1.51B
Total Debt
$5.27B
Free CF
$870.6M
52W Change
46.5%
Annual Financials
Cash vs Debt
Where GMAB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, GMAB finished 30.16% above its 150-day moving average ($29.58) and 28.76% above its 200-day moving average ($29.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GMAB overbought or oversold?
At the October 20, 2026 close, GMAB's RSI(14) was 61.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, GMAB has $1.51B in cash with $5.27B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $870.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 14.0% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.09B (2022) to $3.72B (2025), reflecting a 78% increase over the period.
The relatively low beta of 0.65 suggests GMAB is a less volatile holding compared to the broader index. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Genmab A/S and its sector.